Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29628428 | 1.00 | SIRT3 (0.45) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| Hydrochloric Acid SCHEMBL15953194 | 0.98 | SIRT3 (0.44) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| Hydrochloric Acid SCHEMBL29954682 | 0.98 | SIRT3 (0.44) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| SCHEMBL23110401 | 0.85 | SIRT3 (0.41) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| SCHEMBL708913 | 0.81 | SIRT3 (0.41) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| SCHEMBL28204392 | 0.80 | SIRT3 (0.38) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| Hydrochloric Acid SCHEMBL29958203 | 0.79 | SIRT3 (0.39) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| Hydrochloric Acid SCHEMBL14797240 | 0.79 | SIRT3 (0.39) | SIRT3TDP1CYP2A6CYP2E1CYP3A4 | |
| SCHEMBL28376434 | 0.76 | KDM4E (0.38) | SIRT3TDP1NAPRT | |
| SCHEMBL361105 | 0.74 | GAA (0.46) | SIRT3TDP1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 722 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111640954-A | Preparation method and application of boron-doped porous graphene cathode catalyst | 上海交通大学 | 2020-09-08 | — | — | CN | claimed |
| US-10385046-B1 | Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2019-08-20 | — | — | US | claimed |
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260124222-A1 | ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12534461-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12421257-B2 | Compositions and methods for inhibiting group II intron RNA | YALE UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| EP-3351533-B1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-20250026743-A1 | HETEROARYL-LINKED ANALOGS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2025-01-23 | — | — | US | disclosed |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240390350-A1 | PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2024-11-28 | — | — | US | disclosed |
| WO-2003027094-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-6235758-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-22 | — | — | US | disclosed |
| EP-0808312-B1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 2000-11-02 | — | — | EP | disclosed |
| US-5990133-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS ANXIETY OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-11-23 | — | — | US | disclosed |
| EP-0808312-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996023783-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1996-08-08 | — | — | WO | disclosed |
| US-5358948-A | Psychological, nervous system disorders | GLAXCO GROUP LIMITED (GB) | 1994-10-25 | — | — | US | disclosed |
| WO-1993006084-A1 | BENZANILIDE DERIVATIVES AS 5-HT1D ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1993-04-01 | — | — | WO | disclosed |
| EP-0533267-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421257-B2 | Compositions and methods for inhibiting group II intron RNA | NSUN2, RBM22, RNGTT | SIRT3 3439/4885TDP1 1531/4885CYP2A6 4012/4885 |
| US-12534461-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | SNCA, HCRTR2, HTT | SIRT3 692/4885TDP1 1655/4885CYP2A6 2097/4885 |
| US-20250026743-A1 | HETEROARYL-LINKED ANALOGS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | SIRT3 3033/4885TDP1 1963/4885CYP2A6 2886/4885 |
| US-20240390350-A1 | PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | SIRT3 3227/4885TDP1 1786/4885CYP2A6 3001/4885 |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | SIRT3 1179/4885TDP1 472/4885CYP2A6 298/4885 |
| US-10385046-B1 | Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders | SNCA, PARK7, PSEN2 | SIRT3 1579/4885TDP1 64/4885CYP2A6 2561/4885 |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | SIRT3 1141/4885TDP1 1795/4885CYP2A6 4451/4885 |
| US-20260124222-A1 | ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL6B | SIRT3 3439/4885TDP1 2529/4885CYP2A6 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.